Cocrystal Pharma (COCP) AI Stock Analysis

• Market Cap: $15.41M
• Dividend Yield: N/A
• Average Volume (3M): 16.03K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.56
• Revenue Growth: N/A
• EPS Growth: 9.46%
• Country: US
• Employees: 11
• Sector: Healthcare
• Sector Strength: 43
• Industry: Biotechnology
• EPS (TTM): -0.23
• Shares Outstanding: 10,173,790
• 10 Day Avg. Volume: 19,020
• 30 Day Avg. Volume: 16,034
• PEG Ratio: -0.10
• Price to Book (P/B): 1.98
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.97
• Enterprise Value/Market Cap: 0.60
• Enterprise Value/Revenue: 32.15
• Enterprise Value/Gross Profit: -280.57
• Enterprise Value/Ebitda: -0.13
• 1Y Price Target: $10.00
• Price Target Upside: 584.93% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 40 Underperform
• Price Target: ―

Cocrystal Pharma faces significant financial challenges, with no revenue and ongoing operational losses severely affecting its stock score. The technical analysis indicates potential downward pressure, while the negative valuation metrics are concerning. However, recent corporate events provide some positive aspects, suggesting future growth potential. Overall, the company's stock score reflects these mixed factors, indicating substantial risk with some long-term opportunities.

Positive Factors

Drug Development

CDI-988 yields additional positive Phase 1 data.

Efficacy Against Influenza

Cocrystal has announced that studies of its influenza drug, CC-42344, have shown efficacy against the new avian influenza strain H5N1.

Safety and Tolerability

Cocrystal Pharma announced favorable safety and tolerability results at dosage levels of up to 800mg per day for 10 consecutive days from the multiple-ascending dose (MAD) portion of the ongoing Phase 1 study with its oral protease inhibitor CDI-988.

Negative Factors

Antiviral Data Analysis

The low infectivity in this study hindered antiviral data analysis.

Cocrystal Pharma Business Overview & Revenue Model

Company Description

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.

How the Company Makes Money

Cocrystal Pharma generates revenue primarily through collaborative agreements, licensing deals, and research and development contracts with other pharmaceutical companies. These partnerships often include upfront payments, milestone payments, and royalties based on the successful development and commercialization of targeted antiviral therapies. The company's revenue streams are significantly influenced by its ability to advance its drug candidates through clinical trials and secure strategic partnerships that leverage its proprietary drug discovery technology. Additionally, government grants or funding related to its research areas may also contribute to its financials, although this is less consistent compared to contractual collaborations.

Cocrystal Pharma Financial Statement Overview

Summary

Cocrystal Pharma's financial performance is severely impacted by the lack of revenue and ongoing operational losses, as indicated by the low score of 15 for the income statement. While the balance sheet suggests low leverage with a score of 40, the decline in total assets and equity is concerning. Cash flow issues are evident with a score of 25, reflecting negative operating cash flows and liquidity challenges.

Income Statement

Cocrystal Pharma has reported zero revenue for the past three years, indicating a lack of income generation. The company has consistently reported negative EBIT, EBITDA, and net income, reflecting ongoing operational losses and challenges in achieving profitability. The absence of revenue underscores a challenging growth trajectory in the highly competitive biotechnology sector.

Balance Sheet

The company maintains a strong equity position with a low debt-to-equity ratio, suggesting low leverage and a potentially stable financial structure. However, the consistent decline in total assets and stockholders' equity over the years signals potential financial deterioration. The equity ratio remains robust, indicating that a significant portion of the company's assets is financed by equity rather than debt.

Cash Flow

Cocrystal Pharma has experienced declining operating cash flows, reflecting ongoing struggles in cash generation from operations. Despite this, the company manages to maintain a positive free cash flow to net income ratio, suggesting efficient cash flow management relative to its net losses. However, the lack of free cash flow growth and consistent negative operating cash flow highlight ongoing liquidity challenges.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	2.01M
	Gross Profit
-33.00K	0.00	-15.17M	-241.60K	-239.50K	1.78M
	EBIT
-16.06M	-17.88M	-18.56M	-38.83M	-14.22M	-9.59M
	EBITDA
-15.83M	-17.43M	-19.37M	-38.45M	-13.80M	-9.30M
	Net Income Common Stockholders
-15.85M	-17.50M	-17.98M	-38.84M	-14.19M	-9.66M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
6.92M	9.86M	26.35M	37.14M	58.70M	33.01M
	Total Assets
10.66M	13.46M	31.26M	40.84M	79.39M	54.24M
	Total Debt
1.73M	1.81M	1.85M	297.00K	534.00K	596.00K
	Net Debt
-5.19M	-8.05M	-24.50M	-36.85M	-58.17M	-32.41M
	Total Liabilities
1.42M	3.93M	4.88M	1.27M	1.84M	1.74M
	Stockholders Equity
7.30M	9.52M	26.38M	39.57M	77.55M	52.51M
Cash Flow		Free Cash Flow
-14.92M	-16.49M	-14.78M	-21.51M	-12.77M	-10.07M
	Operating Cash Flow
-14.92M	-16.48M	-14.67M	-21.43M	-12.72M	-9.83M
	Investing Cash Flow
0.00	-8.00K	-118.00K	-74.00K	-52.00K	-240.00K
	Financing Cash Flow
0.00	0.00	3.99M	-27.00K	38.47M	35.66M

Cocrystal Pharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.46
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COCP, the sentiment is Negative. The current price of 1.46 is below the 20-day moving average (MA) of 1.53, below the 50-day MA of 1.47, and below the 200-day MA of 1.81, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 48.15 is Neutral, neither overbought nor oversold. The STOCH value of 17.99 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for COCP.

Cocrystal Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	53 Neutral	$5.14B	3.06	-43.57%	2.81%	16.81%	-0.12%
CRIS	46 Neutral	$20.82M	―	-2951.24%	―	14.17%	28.26%
PHGE	44 Neutral	$14.30M	―	-68.18%	―	―	45.24%
MEIP	41 Neutral	$14.66M	―	-89.73%	―	-100.00%	-292.59%
COCP	40 Underperform	$15.41M	―	-106.05%	―	―	9.46%
CLRB	34 Underperform	$12.17M	―	-208.72%	―	―	56.38%
ABP		$15.49M	―	-35.20%	―	―	―

Cocrystal Pharma Corporate Events

Cocrystal Pharma Advances Norovirus Antiviral Candidate CDI-988

On April 24, 2025, Cocrystal Pharma announced that its norovirus oral antiviral candidate, CDI-988, demonstrated potent activity against the emerging GII.17 norovirus variants, which have become more prevalent than the GII.4 strain in recent years. The company reported favorable safety and tolerability results from a Phase 1 study and plans to initiate a human challenge study in 2025 to further evaluate CDI-988 as a potential treatment and prevention for norovirus infection. This development positions Cocrystal Pharma as a significant player in addressing the urgent need for effective norovirus treatments, potentially impacting the industry by offering a first-in-class oral antiviral solution.

Spark’s Take on COCP Stock

According to Spark, TipRanks’ AI Analyst, COCP is a Underperform.

Cocrystal Pharma’s financial challenges, including zero revenue and ongoing losses, heavily weigh down its stock score. Technical indicators are bearish, and the negative P/E ratio further reflects valuation concerns. While the new equity incentive plan is a positive corporate event, it does not substantially improve the outlook given the financial and technical pressures.

To see Spark’s full report on COCP stock, click here.

Cocrystal Pharma Presents to Investment Community

On April 23, 2025, Cocrystal Pharma, Inc. presented to members of the investment community. The presentation’s content is not considered filed under the Securities Exchange Act of 1934, indicating it may not impact the company’s legal obligations under this act.

Spark’s Take on COCP Stock

According to Spark, TipRanks’ AI Analyst, COCP is a Underperform.

Cocrystal Pharma’s financial challenges, including zero revenue and ongoing losses, heavily weigh down its stock score. Technical indicators are bearish, and the negative P/E ratio further reflects valuation concerns. While the new equity incentive plan is a positive corporate event, it does not substantially improve the outlook given the financial and technical pressures.

To see Spark’s full report on COCP stock, click here.

Cocrystal Pharma Approves 2025 Equity Incentive Plan

Cocrystal Pharma, Inc.’s Board of Directors approved the 2025 Equity Incentive Plan on April 2, 2025, with an effective date of March 31, 2025. The plan, subject to shareholder approval, aims to authorize up to 1,500,000 shares of common stock for issuance, with annual increases, to incentivize employees, consultants, officers, and directors. This strategic move is designed to foster company growth by aligning the interests of key personnel with the company’s prosperity, potentially enhancing its market position and attractiveness to talented individuals.

Spark’s Take on COCP Stock

According to Spark, TipRanks’ AI Analyst, COCP is a Underperform.

Cocrystal Pharma faces significant financial challenges, with no revenue and ongoing operational losses impacting its financial health. Technical indicators are bearish, suggesting the stock may continue to face downward pressure. While the recent positive Phase 1 study results offer some potential, the overall financial and market conditions present substantial risks.

To see Spark’s full report on COCP stock, click here.